Another important facet of risk stratification of patients with CLL is the somatic hypermutation (SHM) status of the B cell receptor (BcR) immunoglobulin heavy variable (IGHV) gene (16). The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.